New Alzheimer's Treatment Strategy Reverses Cognitive Decline in Mice

FLAV-27 is an inhibitor that targets EHMT2 (G9a).

EHMT2 (G9a) is involved in epigenetic regulation in the brain.

FLAV-27 is described as the first inhibitor of its kind targeting EHMT2/G9a and aims to act on upstream changes in gene expression.

Current Alzheimer's therapies target amyloid-beta plaques.

Monoclonal antibodies lecanemab and donanemab slow cognitive decline by around 30 percent. Aina Bellver-Sanchis is a molecular biologist at the University of Barcelona Institute of Neurosciences.